Patient Safety Organizations: Expired Listing From the Surgical Momentum PSO, 12228-12229 [2017-03999]
Download as PDF
<![CDATA[
12228
Federal Register / Vol. 82, No. 39 / Wednesday, March 1, 2017 / Notices
indicated. The applications will also be
available for inspection at the offices of
the Board of Governors. Interested
persons may express their views in
writing on the standards enumerated in
the BHC Act (12 U.S.C. 1842(c)). If the
proposal also involves the acquisition of
a nonbanking company, the review also
includes whether the acquisition of the
nonbanking company complies with the
standards in section 4 of the BHC Act
(12 U.S.C. 1843). Unless otherwise
noted, nonbanking activities will be
conducted throughout the United States.
Unless otherwise noted, comments
regarding each of these applications
must be received at the Reserve Bank
indicated or the offices of the Board of
Governors not later than March 22,
2017.
A. Federal Reserve Bank of St. Louis
(David L. Hubbard, Senior Manager)
P.O. Box 442, St. Louis, Missouri
63166–2034. Comments can also be sent
electronically to
Comments.applications@stls.frb.org:
1. Cross County Bancshares, Inc.,
Wynne, Arkansas; to acquire additional
shares, for a total of 24.9 percent of
Central Bank, Little Rock, Arkansas.
Board of Governors of the Federal Reserve
System, February 24, 2017.
Yao-Chin Chao,
Assistant Secretary of the Board.
[FR Doc. 2017–03938 Filed 2–28–17; 8:45 am]
BILLING CODE 6210–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and
Quality
Meeting of the National Advisory
Council for Healthcare Research and
Quality
Agency for Healthcare Research
and Quality (AHRQ), HHS.
ACTION: Notice of public meeting.
AGENCY:
In accordance with section
10(a) of the Federal Advisory Committee
Act, 5 U.S.C. App. 2, this notice
announces a meeting of the National
Advisory Council for Healthcare
Research and Quality.
DATES: The meeting will be held on
Friday, March 24, 2017, from 8:30 a.m.
to 2:45 p.m.
ADDRESSES: The meeting will be held at
the Hubert H. Humphrey Building,
Room 800, 200 Independence Avenue
SW., Washington, DC 20201.
FOR FURTHER INFORMATION CONTACT:
Jaime Zimmerman, Designated
Management Official, at the Agency for
asabaliauskas on DSK3SPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:09 Feb 28, 2017
Jkt 241001
Healthcare Research and Quality, 5600
Fishers Lane, Mail Stop 06E37A,
Rockville, Maryland, 20857, (301) 427–
1456. For press-related information,
please contact Alison Hunt at (301) 427–
1244 or Alison.Hunt@ahrq.hhs.gov.
If sign language interpretation or other
reasonable accommodation for a
disability is needed, please contact the
Food and Drug Administration (FDA)
Office of Equal Employment
Opportunity and Diversity Management
on (301) 827–4840, no later than Friday,
March 17, 2017. The agenda, roster, and
minutes will be available from Ms.
Bonnie Campbell, Committee
Management Officer, Agency for
Healthcare Research and Quality, 5600
Fishers Lane, Rockville, Maryland,
20857. Ms. Campbell’s phone number is
(301) 427–1554.
www.AHRQ.gov no later than Friday,
March 17, 2017.
SUPPLEMENTARY INFORMATION:
SUMMARY:
I. Purpose
The National Advisory Council for
Healthcare Research and Quality is
authorized by Section 941 of the Public
Health Service Act, 42 U.S.C. 299c. In
accordance with its statutory mandate,
the Council is to advise the Secretary of
the Department of Health and Human
Services and the Director of AHRQ on
matters related to AHRQ’s conduct of its
mission including providing guidance
on (A) priorities for health care research,
(B) the field of health care research
including training needs and
information dissemination on health
care quality and (C) the role of the
Agency in light of private sector activity
and opportunities for public private
partnerships. The Council is composed
of members of the public, appointed by
the Secretary, and Federal ex-officio
members specified in the authorizing
legislation.
II. Agenda
The Council meeting will convene at
8:30 a.m., with the call to order by the
Council Chair and approval of previous
Council summary notes. The meeting is
open to the public and will be available
via webcast at
www.webconferences.com/ahrq. The
meeting will begin with an update on
AHRQ’s current research, programs, and
initiatives. The agenda will feature
discussions on the learning health care
system, Medical Expenditure Panel
Survey (MEPS), and AHRQ’s work in
rural areas. The final agenda will be
available on the AHRQ Web site at
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
Sharon B. Arnold,
Acting Director.
[FR Doc. 2017–03998 Filed 2–28–17; 8:45 am]
BILLING CODE 4160–90–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and
Quality
Patient Safety Organizations: Expired
Listing From the Surgical Momentum
PSO
Agency for Healthcare Research
and Quality (AHRQ), Department of
Health and Human Services (HHS).
ACTION: Notice of delisting.
AGENCY:
The Patient Safety and
Quality Improvement Act of 2005, 42
U.S.C. 299b–21 to b–26, (Patient Safety
Act) and the related Patient Safety and
Quality Improvement Final Rule, 42
CFR part 3 (Patient Safety Rule),
published in the Federal Register on
November 21, 2008, 73 FR 70732–
70814, establish a framework by which
hospitals, doctors, and other health care
providers may voluntarily report
information to Patient Safety
Organizations (PSOs), on a privileged
and confidential basis, for the
aggregation and analysis of patient
safety events. The Patient Safety Rule
authorizes AHRQ, on behalf of the
Secretary of HHS, to list as a PSO an
entity that attests that it meets the
statutory and regulatory requirements
for listing. A PSO can be ‘‘delisted’’ by
the Secretary if it is found to no longer
meet the requirements of the Patient
Safety Act and Patient Safety Rule,
when a PSO chooses to voluntarily
relinquish its status as a PSO for any
reason, or when a PSO’s listing expires.
The listing from the Surgical
Momentum PSO has expired and AHRQ
has delisted the PSO accordingly.
DATES: The directories for both listed
and delisted PSOs are ongoing and
reviewed weekly by AHRQ. The
delisting was effective at 12:00 Midnight
ET (2400) on January 21, 2017.
ADDRESSES: Both directories can be
accessed electronically at the following
HHS Web site: https://
www.pso.ahrq.gov/listed.
FOR FURTHER INFORMATION CONTACT:
Eileen Hogan, Center for Quality
Improvement and Patient Safety, AHRQ,
5600 Fishers Lane, Room 06N94B,
Rockville, MD 20857; Telephone (toll
free): (866) 403–3697; Telephone (local):
E:\FR\FM\01MRN1.SGM
01MRN1
Federal Register / Vol. 82, No. 39 / Wednesday, March 1, 2017 / Notices
(301) 427–1111; TTY (toll free): (866)
438–7231; TTY (local): (301) 427–1130;
Email: pso@ahrq.hhs.gov.
SUPPLEMENTARY INFORMATION:
Background
The Patient Safety Act authorizes the
listing of PSOs, which are entities or
component organizations whose
mission and primary activity are to
conduct activities to improve patient
safety and the quality of health care
delivery.
HHS issued the Patient Safety Rule to
implement the Patient Safety Act.
AHRQ administers the provisions of the
Patient Safety Act and Patient Safety
Rule relating to the listing and operation
of PSOs. The Patient Safety Rule
authorizes AHRQ to list as a PSO an
entity that attests that it meets the
statutory and regulatory requirements
for listing. A PSO can be ‘‘delisted’’ if
it is found to no longer meet the
requirements of the Patient Safety Act
and Patient Safety Rule, when a PSO
chooses to voluntarily relinquish its
status as a PSO for any reason, or when
a PSO’s listing expires. Section 3.108(d)
of the Patient Safety Rule requires
AHRQ to provide public notice when it
removes an organization from the list of
federally approved PSOs.
The Surgical Momentum PSO, PSO
number P0154, a component entity of
the Surgical Momentum, LLC, chose to
let its listing expire by not seeking
continued listing. Accordingly, the
Surgical Momentum PSO was delisted
effective at 12:00 Midnight ET (2400) on
January 21, 2017.
More information on PSOs can be
obtained through AHRQ’s PSO Web site
at https://www.pso.ahrq.gov.
Sharon B. Arnold,
Acting Director.
[FR Doc. 2017–03999 Filed 2–28–17; 8:45 am]
BILLING CODE 4160–90–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2017–N–0001]
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Blood Products Advisory Committee;
Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) announces a
forthcoming public advisory committee
meeting of the Blood Products Advisory
Committee. The general function of the
SUMMARY:
VerDate Sep<11>2014
18:09 Feb 28, 2017
Jkt 241001
committee is to provide advice and
recommendations to the Agency on
FDA’s regulatory issues. At least one
portion of the meeting will be closed to
the public.
DATES: The meeting will be held on
April 4, 2017, from 8:30 a.m. to 3:45
p.m. and on April 5, 2017, from 8:30
a.m. to 12 p.m.
ADDRESSES: The meeting will be held at
Tommy Douglas Conference Center,
10000 New Hampshire Ave., Silver
Spring, MD 20903. The conference
center’s telephone number is 240–645–
4000. Answers to commonly asked
questions including information
regarding special accommodations due
to a disability, visitor parking, and
transportation may be accessed at:
https://www.tommydouglascenter.com.
FOR FURTHER INFORMATION CONTACT:
Bryan Emery or Joanne Lipkind, Center
for Biologics Evaluation and Research,
Food and Drug Administration, 10903
New Hampshire Ave., Bldg. 71, Rm.
6132, Silver Spring, MD 20993–0002,
240–402–8054, 240–402–8106,
bryan.emery@fda.hhs.gov,
joanne.lipkind@fda.hhs.gov; or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area). A notice in the
Federal Register about last minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly
enough to provide timely notice.
Therefore, you should always check the
Agency’s Web site at https://
www.fda.gov/AdvisoryCommittees/
default.htm and scroll down to the
appropriate advisory committee meeting
link, or call the advisory committee
information line to learn about possible
modifications before coming to the
meeting. For those unable to attend in
person, the meeting will also be
available via Webcast. The Webcast will
be available at the following link for
both days: April 4, 2017, 115th Meeting
of the Blood Products Advisory
Committee—Day 1 at: https://
fda.yorkcast.com/webcast/Play/
bb044b891a7b48ff82cc30b18ece526e1d;
April 5, 2017, 115th Meeting of the
Blood Products Advisory Committee—
Day 2 at: https://fda.yorkcast.com/
webcast/Play/b4068ead1c874966860584
b421dcfd231d.
SUPPLEMENTARY INFORMATION:
Agenda: On April 4, 2017, in open
session, the Committee will discuss
Recombinant Human Coagulation Factor
IX, GlycoPEGylated. In the afternoon, in
open session, the Committee will hear
an update presentation on a summary of
responses to Docket FDA–2016–N–1502:
Blood Donor Deferral Policy for
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
12229
Reducing the Risk of Human
Immunodeficiency Virus Transmission
by Blood and Blood Products.
On April 5, 2017, in open session, the
committee will hear overview
presentations on the research programs
in the Laboratory of Emerging Pathogens
in the Division of Emerging
Transfusion-Transmitted Diseases,
Office of Blood Research and Review,
Center for Biologics Evaluation and
Research, FDA. At the conclusion of the
open session, the meeting will be closed
to permit discussion where disclosure
would constitute an unwarranted
invasion of personal privacy in
accordance with 5 U.S.C 552b(c)(6).
During the closed session, the
Committee will discuss the research
progress made by staff involved in the
intramural research programs and make
recommendations regarding their
personnel actions and staffing decisions.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at: https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee meeting
link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before March 28, 2017.
Oral presentations from the public will
be scheduled between approximately
10:50 a.m. to 11:20 a.m. and will be
scheduled between approximately 3:15
p.m. to 3:45 p.m. on April 4, 2017. Oral
presentations from the public will be
scheduled between approximately 10:15
a.m. and 11:15 a.m. on April 5, 2017.
Those individuals interested in making
formal oral presentations should notify
the contact person and submit a brief
statement of the general nature of the
evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before March 20, 2017. Time allotted
for each presentation may be limited. If
the number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
E:\FR\FM\01MRN1.SGM
01MRN1
]]>Agencies
[Federal Register Volume 82, Number 39 (Wednesday, March 1, 2017)]
[Notices]
[Pages 12228-12229]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-03999]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Healthcare Research and Quality
Patient Safety Organizations: Expired Listing From the Surgical
Momentum PSO
AGENCY: Agency for Healthcare Research and Quality (AHRQ), Department
of Health and Human Services (HHS).
ACTION: Notice of delisting.
-----------------------------------------------------------------------
SUMMARY: The Patient Safety and Quality Improvement Act of 2005, 42
U.S.C. 299b-21 to b-26, (Patient Safety Act) and the related Patient
Safety and Quality Improvement Final Rule, 42 CFR part 3 (Patient
Safety Rule), published in the Federal Register on November 21, 2008,
73 FR 70732-70814, establish a framework by which hospitals, doctors,
and other health care providers may voluntarily report information to
Patient Safety Organizations (PSOs), on a privileged and confidential
basis, for the aggregation and analysis of patient safety events. The
Patient Safety Rule authorizes AHRQ, on behalf of the Secretary of HHS,
to list as a PSO an entity that attests that it meets the statutory and
regulatory requirements for listing. A PSO can be ``delisted'' by the
Secretary if it is found to no longer meet the requirements of the
Patient Safety Act and Patient Safety Rule, when a PSO chooses to
voluntarily relinquish its status as a PSO for any reason, or when a
PSO's listing expires. The listing from the Surgical Momentum PSO has
expired and AHRQ has delisted the PSO accordingly.
DATES: The directories for both listed and delisted PSOs are ongoing
and reviewed weekly by AHRQ. The delisting was effective at 12:00
Midnight ET (2400) on January 21, 2017.
ADDRESSES: Both directories can be accessed electronically at the
following HHS Web site: https://www.pso.ahrq.gov/listed.
FOR FURTHER INFORMATION CONTACT: Eileen Hogan, Center for Quality
Improvement and Patient Safety, AHRQ, 5600 Fishers Lane, Room 06N94B,
Rockville, MD 20857; Telephone (toll free): (866) 403-3697; Telephone
(local):
[[Page 12229]]
(301) 427-1111; TTY (toll free): (866) 438-7231; TTY (local): (301)
427-1130; Email: pso@ahrq.hhs.gov.
SUPPLEMENTARY INFORMATION:
Background
The Patient Safety Act authorizes the listing of PSOs, which are
entities or component organizations whose mission and primary activity
are to conduct activities to improve patient safety and the quality of
health care delivery.
HHS issued the Patient Safety Rule to implement the Patient Safety
Act. AHRQ administers the provisions of the Patient Safety Act and
Patient Safety Rule relating to the listing and operation of PSOs. The
Patient Safety Rule authorizes AHRQ to list as a PSO an entity that
attests that it meets the statutory and regulatory requirements for
listing. A PSO can be ``delisted'' if it is found to no longer meet the
requirements of the Patient Safety Act and Patient Safety Rule, when a
PSO chooses to voluntarily relinquish its status as a PSO for any
reason, or when a PSO's listing expires. Section 3.108(d) of the
Patient Safety Rule requires AHRQ to provide public notice when it
removes an organization from the list of federally approved PSOs.
The Surgical Momentum PSO, PSO number P0154, a component entity of
the Surgical Momentum, LLC, chose to let its listing expire by not
seeking continued listing. Accordingly, the Surgical Momentum PSO was
delisted effective at 12:00 Midnight ET (2400) on January 21, 2017.
More information on PSOs can be obtained through AHRQ's PSO Web
site at https://www.pso.ahrq.gov.
Sharon B. Arnold,
Acting Director.
[FR Doc. 2017-03999 Filed 2-28-17; 8:45 am]
BILLING CODE 4160-90-P
